Figure 1 Newly diagnosed HIV infection in Australia by yyear. Nu umber. Year. HIV diagnoses. Source: State/Territory health authorities

Transcription

1 Figure 1 Newly diagnosed HIV infection in Australia by yyear 25 2 Nu umber HIV diagnoses Source: State/Territory health authorities

2 rate per 1 Age stand dardised Figure 2 Newly diagnosed HIV infection, , by year and State/Territory NSW QLD VIC ACT NT SA TAS WA Source: State/Territory health authorities

3 Figure 3 Newly diagnosed HIV infection in Australia, , by newly acquired HIV status and year Num mber 1,3 1,2 1,1 1, Newly acquired HIV Other HIV diagnoses Source: State/Territory health authorities

4 Age standa ardised ra ate per Figure 4 Newly acquired HIV infection, , by State/Territory and year NSW QLD VIC ACT NT SA TAS WA Source: State/Territory health authorities

5 Figure 5 Newly diagnosed HIV infection and diagnoses of newly acquired HIV infection in Australia, , by HIV exposure category Newly diagnosed HIV Newly acquired HIV 6% 1% 3% 9% 2% 25% 2% 3% 64% 85% Men who have sex with men Men who have sex with men and injecting drug use Injecting drug use Heterosexual contact Other/undetermined Source: State/Territory health authorities

6 Figure 6 Rate of HIV diagnosis in Australia, , by country/region of birth and year Age standardis sed rate per 1 South/Central America and the Caribbean North America Asia Sub-Saharan Africa Middle East/North Africa Other Europe United Kingdom and Ireland Other Oceania Australia Source: State/Territory health authorities

7 Figure 7 HIV prevalence in selected countries New Zealand China Australia United Kingdom Italy Indonesia Viet Nam Malaysia Canada Spain Myanmar France United States Papua New Guinea Cambodia Thailand HIV prevalence per 1

8 Figure 8 Hepatitis B notifications, , by year and sex cation ra ate per 1 Notifi Male Female Source: National Notifiable Diseases Surveillance System

9 Figure 9 Hepatitis B notifications, , by year and age group N otificatio on rate per Source: National Notifiable Diseases Surveillance System

10 er 1 No otificatio on rate p Figure 1 Newly acquired hepatitis B notifications, , by year and sex Male Female Source: National Notifiable Diseases Surveillance System

11 No otificatio on rate pe er 1 Figure 11 Newly acquired hepatitis B notifications, , by year and age group Source: National Notifiable Diseases Surveillance System

12 Figure 12 Estimated prevalence of chronic hepatitis B infection in Australia by country of birth New Zealand United Kingdom Australia Italy Sri Lanka Greece India Korea, Republic of (South) Malaysia Fiji Philippinesi Cambodia Afghanistan Taiwan China (excluding Taiwan) Viet Nam Hepatitis B prevalence (%) Source: VIDRL/ASHM Hepatitis B Epidemiology Mapping Project

13 Figure 13 Hepatitis C notifications, , by year and age group er 1 No otificatio on rate p Source: National Notifiable Diseases Surveillance System

14 Figure 14 Newly acquired hepatitis C notifications, , by year and age group er 1 No otificatio on rate p Source: National Notifiable Diseases Surveillance System

15 Figure 15 Chlamydia notifications, , by year and sex 45 4 Notif fication ra ate per Females Males Source: National Notifiable Diseases Surveillance System

16 Figure 16 Chlamydia notifications, , by year and age group Notifica ation rate per 1 2, 1,8 1,6 1,4 1,2 1, Source: National Notifiable Diseases Surveillance System

17 Figure 17 Gonorrhoea notifications, , by year and sex Notifica tion rate per Male Female Source: National Notifiable Diseases Surveillance System

18 Figure 18 Gonorrhoea notifications, , by year and age group per 1 Notificat tion rate Source: National Notifiable Diseases Surveillance System

19 Figure 19 Infectious syphilis notifications, , by year and sex 15 No otificatio on rate p er Male Female Source: National Notifiable Diseases Surveillance System

20 per 1 Figure 2 Infectious syphilis notifications, , by year and age group ion rate Notificat Source: National Notifiable Diseases Surveillance System

21 Figure 21 Newly acquired HIV infection among men who have sex with men seen at sexual health clinics, , by year and age group HIV infe ection (% %) Newly acquired Less than 25 years 25 years and older Source: Collaborative group on sentinel surveillance in sexual health clinics

22 Figure 22 Prevalence of condom-less anal intercourse with casual partners reported by men in Gay Community Periodic Surveys 5% 4% Percen ntage 3% 2% 1% % Adelaide Canberra Melbourne Perth Queensland Sydney Source: Gay Community Periodic Surveys

23 18 Figure 23 Gonococcal rectal infection among men, , by State/Territory and year 16 Diagn osis rate per NSW NT QLD SA VIC WA Source: Australian Gonococcal Surveillance Programme

24 5. Figure 24 HIV diagnoses in the Australian born population, , by Aboriginal and Torres Strait Islander status and year rate per 1 Age stand dardised non-indigenous Indigenous Source: State/Territory health authorities

25 Figure 25 Newly diagnosed HIV infection, , by Aboriginal and Torres Strait Islander status t and HIV exposure category Aboriginal and Torres Strait Islander Australian-born non-indigenous 8% 13% 4% 21% 3% 4% 12% 8% 51% 76% Men who have sex with men Men who have sex with men and injecting drug use Injecting drug use Heterosexual contact Undetermined Source: State/Territory health authorities

26 Figure 26 Hepatitis C notifications, , by Aboriginal and Torres Strait Islander status, State/Territory and year Age standar rdised rat te per Aboriginal and Torres Strait Islander NT SA TAS WA Non-Indigenous Source: National Notifiable Diseases Surveillance System

27 Figure 27 Chlamydia notifications, , by Aboriginal and Torres Strait Islander status, State/Territory and year Age standar rdised rat te per Aboriginal and Torres Strait Islander NT QLD SA TAS WA Non-Indigenous Source: National Notifiable Diseases Surveillance System

28 Figure 28 Gonorrhoea notifications, , by Aboriginal and Torres Strait Islander status, State/Territory and year Age sta andardise ed rate pe er 1 Aboriginal and Torres Strait Islander Non-Indigenous ACT NT QLD SA TAS VIC WA Source: National Notifiable Diseases Surveillance System

29 Figure 29 Infectious syphilis notifications, , by Aboriginal and Torres Strait Islander status, State/Territory and year Age sta andardise ed rate pe er Aboriginal and Torres Strait Islander Non-Indigenous ACT NSW NT QLD SA TAS VIC WA Source: National Notifiable Diseases Surveillance System

30 Figure 3 HIV and hepatitis C prevalence in needle and syringe programs, , by year and sex Preval lence (% %) Hepatitis C, female Hepatitis C, male HIV, female HIV, male Source: Collaboration of Australian Needle and Syringe Programs

31 Figure 31 HIV prevalence at needle and syringe programs, 213, by sexual identity Prevale ence (%) Heterosexual Bisexual Homosexual Sexual identity Male Female Source: Collaboration of Australian Needle and Syringe Programs

32 Figure 32 Prevalence of sharing among recent initiates to injecting 1 seen at needle and syringe programs, , by year and sex lence (% %) Preva Female Male 1 With a history of injecting drug use less than five years who were tested for HIV or hepatitis C Source: Collaboration of Australian Needle and Syringe Programs

33 Figure 33 Newly diagnosed HIV infection among men who report an exposure other than sex with men, , by year and exposure category Number From a high prevalence country Heterosexual contact with partner from a high prevalence country Heterosexual contact, partner with other risk Heterosexual contact, not further specified Injecting drug use or partner an injecting drug user Other/undetermined Source: State/Territory health authorities

34 Figure 34 Newly diagnosed HIV among women, , by year and HIV exposure category Numb ber From a high prevalence country Heterosexual contact, bisexual partner Heterosexual contact, not further specified Other/undetermined Heterosexual contact with partner from a high prevalence country Heterosexual contact, partner with other risk Injecting drug use or partner an injecting drug user Source: State/Territory health authorities

35 Figure 35 HIV infection attributed to heterosexual contact, , by region of birth 1% 1% 1% Australia Other Oceania 21% 29% United Kingdom and Ireland Other Europe Middle East/North Africa Sub-Saharan Africa Asia 3% 3% 3% 4% 7% North America South/Central America and the Caribbean Not reported Source: State/Territory health authorities

36 Figure 36 HIV prevalence among heterosexually active men seen at sexual health clinics, i , by year and HIV exposure category.5.4 Percen ntage (%) Heterosexual contact in Australia Injecting drug use Heterosexual contact overseas Source: Collaborative group on sentinel surveillance in sexual health clinics

37 Figure 37 HIV prevalence among heterosexually active women seen at sexual health clinics, , by year and HIV exposure category.4.3 Percen ntage (%) Heterosexual contact in Australia Injecting drug use Heterosexual contact overseas Sex work Source: Collaborative group on sentinel surveillance in sexual health clinics

38 Figure 38 HIV and hepatitis C prevalence per 1 donations in blood donors, , by year lence pe er 1 onations HI IV preva d HIV Hepatitis C Source: Australian Red Cross Blood Service

39 Figure 39: Proportion of Australian born women diagnosed with genital warts at first visit, , by year and age group 16 War rts diagno oses (%) <21 years 21-3 years >3 years * The dotted line represents the start of the national HPV vaccination program in mid-27 Source: Genital Warts Surveillance Network

40 Figure 4: Proportion of Australian born heterosexual men diagnosed with genital warts at first visit, , by year and age group 22 Warts diagnoses s (%) <21 years 21-3 years >3 years * The dotted line represents the start of the national HPV vaccination program in mid-27 Source: Genital Warts Surveillance Network

41 Figure 41: Proportion of Australian born homosexual and bisexual men diagnosed with genital warts at first visit, , by year 1 Warts diag gnoses (%) homosexual bisexual * The dotted line represents the start of the national HPV vaccination program in mid-27 Source: Genital Warts Surveillance Network

42 Figure 42 Diagnoses of newly acquired HIV infection and CD4+ cell count among other new HIV diagnoses in Australia, , by year 1% 9% 8% 7% 6% 5% 4% 3% 2% 1% % Newly acquired HIV < Source: State/Territory health authorities

43 Percen ntage 6 5 Figure 43 Late and advanced HIV diagnoses 1, , by year and exposure category Men who have sex with Injecting drug use Heterosexual contact Other/undetermined Advanced HIV diagnosis Exposure category Late HIV diagnosis Late HIV diagnosis is defined as newly diagnosed HIV infection with a CD4 count of less than 35 cells/µl and advanced HIV infection with a CD4+ cell count of less than 2 cells/µl Source: State/Territory health authorities

44 Figure 44 Late and advanced HIV diagnoses 1, , by year and region of birth Percenta age Australia Other Oceania United Kingdom and Ireland Advanced HIV diagnosis Other Europe Middle East/ North Africa Sub-Saharan Africa Country/region of birth Asia Late HIV diagnosis Northern America South/Central America and the Caribbean 1 Late HIV diagnosis is defined as newly diagnosed HIV infection with a CD4 count of less than 35 cells/µl and advanced HIV infection with a CD4+ cell count of less than 2 cells/µl Source: State/Territory health authorities

45 (%) Prev valence Figure 45 Treatment uptake among people p enrolled on the Australian HIV Observational Database, Rx NAIVE Mono and Double therapy 3+NRTI+/-PI, no NNRTI, no II 3+ NRTI+NNRTI, no PI, no II 3+ NNRTI+PI,+/-NRTI, no II 3+ II,+/-NRTI,+/-NNRTI,+/-PI II = Integrase Inhibitor Source: Australian HIV Observational Database

46 Figure 46 HIV viral load and CD4+ cell count among people enrolled on the Australian HIV Observational Database, , by year ral load (%) Undetec ctable vi CD4 cell coun nt (cells/µ µl) Mean CD4+ count Undetectable viral load Source: Australian HIV Observational Database 1. Undetectable viral load equals 5 copies/ml or less

47 Figure 47 Estimated number of people e dispensed sed drugs for HIV infection, , by class of drug and year Numb ber NRTI* NNRTI* Protease Inhibitor Entry inhibitor Integrase inhibitor Combination class agents * Includes NRTI/NNRTIs in fixed dose combinations with other classes Source: Highly Specialised Drugs Program

48 Numbe er Figure 48 Estimated number of people dispensed drugs for hepatitis C infection, , by year Hepatitis C infection Source: Highly Specialised Drugs Program